The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tokumaru, S.
Right arrow Articles by Hashimoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tokumaru, S.
Right arrow Articles by Hashimoto, K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
The Journal of Immunology, 2005, 175: 4662-4668.
Copyright © 2005 by The American Association of Immunologists

Induction of Keratinocyte Migration via Transactivation of the Epidermal Growth Factor Receptor by the Antimicrobial Peptide LL-371

Sho Tokumaru2,*, Koji Sayama2,3,*, Yuji Shirakata*, Hitoshi Komatsuzawa{dagger}, Kazuhisa Ouhara{dagger}, Yasushi Hanakawa*, Yoko Yahata*, Xiuju Dai*, Mikiko Tohyama*, Hiroshi Nagai*, Lujun Yang*, Shigeki Higashiyama{ddagger}, Akihiko Yoshimura§, Motoyuki Sugai{dagger} and Koji Hashimoto*

* Department of Dermatology, Ehime University School of Medicine, Ehime, Japan; {dagger} Department of Bacteriology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; {ddagger} Department of Molecular and Cellular Biology, Division of Biochemistry and Molecular Genetics, Ehime University School of Medicine, Ehime, Japan; and § Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The closure of skin wounds is essential for resistance against microbial pathogens, and keratinocyte migration is an important step in skin wound healing. Cathelicidin hCAP18/LL-37 is an innate antimicrobial peptide that is expressed in the skin and acts to eliminate microbial pathogens. Because hCAP18/LL-37 is up-regulated at skin wound sites, we hypothesized that LL-37 induces keratinocyte migration. In this study, we found that 1 µg/ml LL-37 induced the maximum level of keratinocyte migration in the Boyden chamber assay. In addition, LL-37 phosphorylated the epidermal growth factor receptor (EGFR) after 10 min, which suggests that LL-37-induced keratinocyte migration occurs via EGFR transactivation. To test this assumption, we used inhibitors that block the sequential steps of EGFR transactivation, such as OSU8-1, CRM197, anti-EGFR no. 225 Ab, and AG1478. All of these inhibitors completely blocked LL-37-induced keratinocyte migration, which indicates that migration occurs via HB-EGF-mediated EGFR transactivation. Furthermore, CRM197, anti-EGFR no. 225, and AG1478 blocked the LL-37-induced phosphorylation of STAT3, and transfection with a dominant-negative mutant of STAT3 abolished LL-37-induced keratinocyte migration, indicating the involvement of the STAT3 pathway downstream of EGFR transactivation. Finally, we tested whether the suppressor of cytokine signaling (SOCS)/cytokine-inducible Src homology 2-containing protein (CIS) family of negative regulators of STAT3 regulates LL-37-induced keratinocyte migration. Transfection with SOCS1/Jak2 binding protein or SOCS3/CIS3 almost completely abolished LL-37-induced keratinocyte migration. In conclusion, LL-37 induces keratinocyte migration via heparin-binding-EGF-mediated transactivation of EGFR, and SOCS1/Jak 2 binding and SOCS3/CIS3 negatively regulate this migration. The results of this study suggest that LL-37 closes skin wounds by the induction of keratinocyte migration.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Antimicrobial peptides are short amino acid sequences that can kill a variety of microbial pathogens. The major human antimicrobial peptides are the defensins and cathelicidin (1, 2, 3, 4). Defensins are cysteine-rich cationic peptides and are further classified as {alpha}- or {beta}-defensins based on structure. The {alpha}-defensins 1–4 (HNP1–4) are produced by neutrophils (5, 6), and the {alpha}-defensins 5 and 6 are found in Paneth cells of the gastrointestinal tract (7, 8). The {beta}-defensins 1–4 (hBD 1–4)4 are produced by epithelial tissues (9, 10, 11, 12). hCAP18/LL-37 is the only human antimicrobial peptide that has been identified as a member of the cathelicidin family; it is produced in many tissues and cell types (4) and is processed to LL-37 in neutrophils (13). In the skin, epidermal keratinocytes produce hBD1–4 and hCAP18/LL-37 (4, 9, 10, 11, 12). Murakami (14) analyzed sweat samples and identified three additional forms of cathelicidin peptide which deliver innate effector molecules in the absence of inflammation. Mast cells in the dermis were also found to produce hCAP18/LL-37 (15).

The epidermis plays an essential role in resistance against microbial-borne disease, as it is constantly exposed to a variety of microbial pathogens. The hBDs and hCAP18/LL-37 play major roles in this innate immune system (16). In addition, the epidermis functions as a physical barrier to microbial pathogens. However, once this physical barrier is disrupted by wounding, microbial pathogens can invade the underlying tissue. Therefore, the efficient closure of skin wounds is vital to the maintenance of homeostasis. In contrast, wounded skin expresses antimicrobial peptides, such as hCAP18/LL-37 and defensins (17, 18, 19). Although antimicrobial peptides were originally identified as molecules that kill microbial pathogens, there is strong evidence that these peptides have functions in antimicrobial immunity other than direct antimicrobial activity.

Recently, it was revealed that these antimicrobial peptides are multifunctional proteins (20). Although hBDs are chemotactic for dendritic cells, LL-37 is chemotactic for neutrophils, monocytes, and T cells, but not for dendritic cells (3, 21, 22). LL-37 modulates dendritic cell differentiation and promotes Th1 responses (23). In the case of endothelial cells, LL-37 induces angiogenesis that is mediated by the formyl peptide receptor-like 1 receptor (24). In wounded skin, hCAP18/LL-37 is up-regulated, whereas the hCAP18/LL-37 levels in chronic ulcers are low (19). Furthermore, anti-LL-37 Ab inhibits re-epithelialization of skin wounds (19). These findings suggest that, apart from having antimicrobial activity, LL-37 plays an important role in wound healing.

The migration of epidermal keratinocytes is an important step in skin wound healing. Growth factors and the epidermal growth factor (EGF) receptor (EGFR) are involved in keratinocyte migration and proliferation (25, 26). Extracellular stimuli from the EGF and non-EGF families can activate the EGFR. These diverse stimuli include numerous agonists for heptahelical G-protein-coupled receptors, cytokines, and integrins (27, 28). The activation of the EGFR by non-EGFR ligands is called transactivation (27) and is mediated, at least in part, by heparin-binding EGF (HB-EGF), which is cleaved from its membrane-anchored form (pro-HB-EGF) by a specific metalloproteinase (29, 30). Recently, the transactivation of EGFR by LL-37 was reported for airway epithelial cells (31), which suggests that LL-37 induces keratinocyte migration via EGFR transactivation during skin wound healing.

The intracellular signaling molecule, STAT3, is involved in keratinocyte migration (32). The STAT family consists of STATs 1, 2, 3, 4, 5a, 5b, and 6. STATs and adaptor molecules are sequentially activated upon the binding of a cytokine to its receptor. After phosphorylation, STAT forms a homodimer or heterodimer, translocates into the nucleus, and initiates the transcription of target genes (33). These STAT signaling pathways are negatively regulated by the suppressor of a cytokine signaling (SOCS)/cytokine-inducible Src homology 2-containing protein (CIS) family, thereby avoiding oversignaling (34). In human keratinocytes, SOCS3/CIS3 negatively regulates hepatocyte growth factor-induced migration (35). Therefore, the STAT3-SOCS/CIS family may also be involved in LL-37-induced keratinocyte migration.

In this study, we demonstrate that LL-37 induces keratinocyte migration, and we examine the molecular mechanisms underlying EGFR transactivation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Synthesis of LL-37

LL-37 was synthesized using a peptide synthesizer (Shimazu), as described previously (36). The peptide was purified using reverse-phase HPLC with an octadecyl-4PW column (Tosoh) and a linear gradient of aqueous 0.05% trifluoroacetic acid to 100% acetonitrile that contained 0.05% trifluoroacetic acid, and the sample was then lyophilized to remove the organic solvent. To confirm peptide purity and quality, mass spectrometry using the MALDI/TOF-mass spectrometry method was performed with Voyager (PerSeptive Biosystems). The peptides were assayed for LPS contamination by the Limulus test (Seikagaku).

Reagents and Abs

The following Abs were used: STAT3 (clone 84; BD Transduction Laboratories), phospho-STAT3 (no. 9131; Cell Signaling Technology), EGFR (clone 13; BD Transduction Laboratories), and phospho-EGFR (clone 9H2; Upstate Biotechnology) and EGFR neutralizing Ab (clone 225; Oncogene Research Products). AG1478 and CRM197 were purchased from Merck. OSU8–1 (37) was a gift from Canebo Science.

Keratinocyte culture

Primary normal human keratinocytes were isolated from normal human skin and cultured as previously described (38). The human skin samples were obtained after plastic surgery under a protocol approved by the Institutional Review Board of Ehime University School of Medicine. The skin samples were cut into 3- to 5-mm pieces and incubated with 250 U/ml dispase (Godoshusei) in DMEM overnight at 4°C. After separation of the epidermis from the dermis, the epidermal sheets were incubated in a 0.25% trypsin solution for 10 min at 37°C and teased with forceps. The keratinocytes were collected by centrifugation and were further cultured in MCDB153 medium that was supplemented with insulin (1 µg/ml), hydrocortisone (0.5 µM), ethanolamine (0.1 mM), phosphoethanolamine (0.1 mM), bovine hypothalamic extract (BHE; 50 µg/ml), and Ca2+ (0.1 mM). This supplement has been described elsewhere (39).

Migration assay

Keratinocyte migration was assayed quantitatively with a Boyden chamber, as described previously (40). Designated amounts of LL-37 were added to the bottom wells of a 48-well Boyden chamber (Neuro Probe), and an 8-µm pore-size polyvinylpyrrolidone-free polycarbonate membrane (Neuro Probe) was placed on the wells. The membrane was precoated with type I collagen (10 µg/ml in PBS; Nitta Gelatin) at room temperature for 1 h and then washed extensively with PBS. Subconfluent keratinocytes were harvested with trypsin-EDTA (0.05% trypsin and 0.5 mM EDTA) and resuspended in culture medium without BHE at 1 x 105 cells/ml. A 50-µl aliquot of the keratinocyte suspension (5,000 cells/well) was added to the upper wells, and the chamber was incubated overnight at 37°C in a humidified atmosphere of air with 5% CO2. The cells that adhered to the upper surface of the filter membrane were removed by scraping with a rubber blade, and the cells that moved through the filter and stayed on the lower surface of the membrane were considered to be migrated cells. The membrane was fixed with 10% buffered formalin overnight and then stained overnight with Gill’s hematoxylin. The membrane was then mounted between two glass slides with 90% glycerol, and the number of migrated cells was determined by counting under a microscope.

The role of EGFR transactivation in LL-37-induced keratinocyte migration was analyzed by the inhibition of EGFR transactivation with OSU8-1 (37), anti-EGFR neutralizing Ab no. 225, CRM197 (37), and AG1478. OSU8-1 (1 µM), anti-EGFR no. 225 (10 µg/ml), CRM197 (1 µg/ml), and AG1478 (30 nM) were added to the lower chamber together with 1 µg/ml LL-37, and LL-37-induced keratinocyte migration was analyzed as described previously.

Western blotting

Subconfluent keratinocytes were starved for 2 h in BHE-free medium and then stimulated with LL-37 as indicated. The cells were harvested on ice in lysis buffer that contained 5 mM EDTA, 100 µM sodium orthovanadate, 100 µM sodium pyrophosphate, 1 mM sodium fluoride, 5 µM 3,4-dichloroisocumarin, 1 µg/ml aprotinin, and 1% Triton X-100 in PBS. A 20-µg sample of protein was separated on 10% SDS-PAGE and then transferred to a polyvinylidene difluoride membrane. The membranes were blocked overnight at 4°C with 5% skimmed milk in PBS. The blocked membranes were incubated for 6 h with the first Ab as indicated. After three washes with PBS that contained 0.05% Tween 20, the membranes were treated with ABC reagents (Vector Laboratories) for 20 min at room temperature, washed three times with PBS that contained 0.05% Tween 20, treated with ECL detection reagents (Amersham Pharmacia Biotech) for 1 min at room temperature, and exposed to photographic film (Kodak).

Adenovirus vectors (Axs)

STAT3 has a phosphorylation site at tyrosine 705. In dominant-negative mutants of STAT3 (STAT3F), the phosphorylatable tyrosine residues are substituted with phenylalanine. Axs that encode STAT3F (AxCAStat3F), SOCS1/Jak2-binding (JAB) (AxCAJAB), and SOCS3/CIS3 (AxCACIS3) were generated as described previously (41), using the cosmid cassettes and Ad DNA-terminal protein complex method (42). An Ax that encodes lacZ (Ax LacZ) was a gift from Dr. I. Saito (University of Tokyo, Tokyo, Japan). Virus stocks were prepared using a standard procedure (42). Concentrated, purified virus stocks were prepared using a CsCl gradient, and the virus titer was checked using a plaque formation assay. We infected normal human keratinocytes with Axs at a multiplicity of infection (moi) of 5.

Statistical analyses

Data were collected from at least three independent experiments. Quantitative data are expressed as the mean ± SE. Statistical significance was determined by the paired Student t test. Differences were considered to be statistically significant for p < 0.05. The levels of statistical significance are indicated in the figures as follows: *, p < 0.05; **, p < 0.01.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
LL-37 induces keratinocyte migration

Initially, we investigated whether LL-37 induced keratinocyte migration. After the addition of 1 µg/ml LL-37 to cultured normal human keratinocytes, cell migration was observed by phase contrast microscopy. LL-37 induced keratinocyte migration at 12 h compared with the control (Fig. 1A). Next, we quantitatively analyzed LL-37-induced migration using the Boyden chamber assay (Fig. 1B). Various amounts of LL-37 and cultured keratinocytes were added to the lower and upper chambers, respectively. After incubation overnight, the migrated keratinocytes were counted. LL-37 induced a 3-fold increase in keratinocyte migration compared with the control treatment. The optimum concentration of LL-37 to induce migration was 1 µg/ml.



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 1. LL-37-induced keratinocyte migration. A, Keratinocyte migration was observed under the phase contrast microscope. A portion of the keratinocytes was removed from the tissue culture plates by scraping, and the remaining cells were cultured further with 1 µg/ml LL-37. The levels of cell migration were observed at 3 and 12 h. B, Keratinocyte migration was assayed quantitatively using the Boyden chamber. The indicated amounts of LL-37 were added to the bottom wells of a 48-well Boyden chamber, and an 8-µm pore-size polyvinylpyrrolidone-free polycarbonate membrane was placed on the wells. Keratinocytes were added to the upper wells at 5000 cells/well. After overnight incubation, the membrane was stained with Gill’s hematoxylin. The number of cells that had migrated through the filter was determined by counting under a microscope. The data are shown as percentages of the control migration. Each point shows the mean ± SD of quadruplicate measurements. **, p < 0.01.

 
LL-37 phosphorylates EGFR

Because EGFR is involved in keratinocyte migration, we investigated whether EGFR transactivation is involved in LL-37-induced keratinocyte migration by analyzing the phosphorylation of EGFR by LL-37 (Fig. 2). LL-37 phosphorylated EGFR at 10 min, and the phosphorylation persisted for 15 min. The amount of EGFR protein did not change during this time period.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 2. Activation of EGFR by LL-37. Phosphorylation of EGFR by LL-37. Subconfluent keratinocytes were starved for 2 h in BHE-free medium and stimulated with 1 µg/ml LL-37. The cells were harvested into lysis buffer at the indicated times. The phosphorylation of EGFR (p-EGFR) was analyzed by Western blotting. EGFR indicates total EGFR protein.

 
LL-37-induced keratinocyte migration occurs via HB-EGF-mediated EGFR transactivation

The activation of EGFR suggests that LL-37-induced keratinocyte migration is via EGFR transactivation. To confirm this suggestion, we used several inhibitors that block the sequential steps of EGFR transactivation (Figs. 3 and 4B). In EGFR transactivation, extracellular stimuli activate a metalloproteinase on the cell membrane, which cleaves the extracellular domain of the EGF family. The cleaved EGF then binds and phosphorylates EGFR, which transduces the signals into the intracellular signaling pathways. OSU8-1 is a metalloproteinase inhibitor that blocks the shedding of EGF family members (37). CRM197 is a nontoxic mutant of diphtheria toxin that binds to the extracellular domain of the membrane-anchored form of HB-EGF and inhibits the soluble form of HB-EGF, whereas it does not bind to other EGF family members, such as EGF, TGF-{alpha}, amphiregulin, and betacellulin (37). The anti-EGFR no. 225 Ab blocks the binding of EGF family members to the EGFR. AG1478 is an inhibitor of EGFR tyrosine kinase, which blocks the activation of EGFR.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 3. Inhibition of LL-37-induced keratinocyte migration by OSU8-1, CRM197, anti-EGFR no. 225, and AG1478. In the presence of inhibitors of EGFR transactivation, LL-37-induced keratinocyte migration was analyzed in the Boyden chamber assay. The mechanisms of action of these inhibitors are shown in Fig. 7. OSU8-1 (1 µM), CRM197 (1 µg/ml), anti-EGFR no. 225 (10 µg/ml), and AG1478 (30 nM) (A–D, respectively) were added to the lower chamber together with 1.0 µg/ml LL-37, and LL-37-induced keratinocyte migration was analyzed as described in Fig. 1. **, p < 0.01.

 


View larger version (49K):
[in this window]
[in a new window]
  		FIGURE 4. Phosphorylation of STAT3 by LL-37. A, Phosphorylation of STAT3 by LL-37. Subconfluent keratinocytes were starved for 2 h in BHE-free medium, and stimulated with 1 µg/ml LL-37. The cells were harvested into lysis buffer at the indicated time. The phosphorylation of STAT3 (p-STAT3) was analyzed by Western blotting. STAT3 indicates total STAT3 protein. B, Inhibition of LL-37-induced STAT3 phosphorylation by OSU8-1, anti-EGFR no. 225, CRM197, and AG1478. Keratinocytes were pretreated with OSU8-1 (1 µM), anti-EGFR no. 225 (10 µg/ml), CRM197 (1 µg/ml), or AG1478 (30 nM) for 1 h and then stimulated with 1 µg/ml LL-37 for 15 min. The phosphorylation of STAT3 was analyzed by Western blotting.

 
Using these inhibitors, we investigated whether the inhibition of EGFR transactivation blocks LL-37-induced keratinocyte migration. After the addition of OSU8-1, CRM197, anti-EGFR no. 225, and AG1478 to the lower chamber with LL-37, keratinocyte migration was analyzed quantitatively using the Boyden chamber, as shown in Fig. 1. All of the inhibitors, including OSU8-1, CRM197, anti-EGFR no. 225, and AG1478, completely blocked LL-37-induced keratinocyte migration (Fig. 3). As LL-37 phosphorylates EGFR, and because LL-37-induced migration was completely blocked by OSU8-1, CRM197, anti-EGFR no. 225, and AG1478, we conclude that LL-37-induced keratinocyte migration is via HB-EGF-mediated EGFR transactivation.

LL-37 phosphorylates STAT3 via HB-EGF-mediated EGFR transactivation

A previous study has demonstrated that the STAT3 signaling pathway is involved in keratinocyte migration (32). Therefore, we studied the involvement of STAT3 in LL-37-induced keratinocyte migration. LL-37 maximally phosphorylated STAT3 at 15 min as determined by densitometric analysis, and the level of phosphorylation decreased at 25 min (Fig. 4). The amount of STAT3 protein did not change during this time. We also investigated whether LL-37-induced STAT3 phosphorylation occurred via HB-EGF-mediated EGFR transactivation. Keratinocytes were pretreated with OSU8-1, CRM197, anti-EGFR no. 225, and AG1478 for 1 h and were then stimulated with LL-37 for 15 min, followed by Western blot analysis. All of these inhibitors blocked LL-37-induced STAT3 phosphorylation, which again indicates that LL-37-induced STAT3 phosphorylation is via HB-EGF-mediated EGFR transactivation.

STAT3 is essential for LL-37-induced keratinocyte migration

We investigated whether STAT3 is essential for LL-37-induced keratinocyte migration. We constructed dominant-negative mutants of STAT3 (STAT3F) as well as Ax-carrying STAT3F (AxCAStat3F), as described previously (41). AxCAStat3F and the control vector AxLacZ were transfected (moi = 10) into keratinocytes. The expression of STAT3F almost completely blocked both LL-37-induced STAT3 phosphorylation and LL-37-induced keratinocyte migration (Fig. 5). Because STAT3 was phosphorylated by LL-37 and LL-37-induced migration was blocked by STAT3F, we conclude that the phosphorylation of STAT3 is essential for LL-37-induced keratinocyte migration.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 5. Inhibition of LL-37-induced keratinocyte migration by STAT3F. Ax LacZ and AxCAStat3F were transfected into normal human keratinocytes at a moi of 5. After 24 h, the keratinocytes were harvested and transferred to the upper well of the Boyden chamber. Then, 1 µg/ml LL-37 was added to the lower chamber, and keratinocyte migration was analyzed as described in Fig. 1. The numbers of migrated cells are shown as percentages of the control migration. Each point shows the mean ± SD of quadruplicate measurements. *, p < 0.05.

 
SOCS1/JAB and SOCS3/CIS3 inhibit LL-37-induced keratinocyte migration

Because STAT3 is involved in LL-37-induced keratinocyte migration (as shown in Figs. 4 and 5), we analyzed the mechanism of regulation of STAT3 by SOCS1/JAB and SOCS3/CIS3. After the transfection of keratinocytes with AxCAJAB or AxCACIS3, LL-37-induced keratinocyte migration was analyzed quantitatively using the Boyden chamber assay (Fig. 6). The expression of either SOCS1/JAB or SOCS3/CIS3 almost completely blocked LL-37-induced keratinocyte migration. LL-37 induced neither SOCS1/JAB nor SOCS3/CIS3 (data not shown).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 6. Inhibition of LL-37-induced keratinocyte migration by SOCS1/JAB and SOCS3/CIS3. Ax LacZ, AxCAJAB, and AxCACIS3 were transfected into normal human keratinocytes at a moi of 5. After 24 h, the keratinocytes were harvested and transferred to the upper well of the Boyden chamber. Then, 1 µg/ml LL-37 was added to the lower chamber, and keratinocyte migration was analyzed as described in Fig. 1. The numbers of migrated cells are shown as percentages of the control migration. Each point shows the mean ± SD of quadruplicate measurements. **, p < 0.01.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The molecular mechanisms underlying LL-37-induced keratinocyte migration are summarized in Fig. 7. LL-37 activates the metalloproteinase, which cleaves the extracellular domain of HB-EGF. The soluble form of HB-EGF then binds to and phosphorylates EGFR. This, in turn, transduces the signals into the intracellular signaling pathways. STAT3 mediates this signaling pathway, leading to keratinocyte migration. SOCS1/JAB or SOCS3/CIS3 negatively regulates this STAT3 pathway and migration.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 7. Proposed molecular mechanism of LL-37-induced keratinocyte migration. This scheme summarizes the pathway from LL-37 to keratinocyte migration and includes EGFR transactivation and STAT3. LL-37 activates the metalloproteinase, which cleaves the extracellular domain of HB-EGF. The soluble form of HB-EGF then binds and phosphorylates EGFR, which transduces the signals into the intracellular signaling pathways. OSU8-1 is a metalloproteinase inhibitor that blocks the shedding of EGF family proteins. CRM197 is a nontoxic mutant of diphtheria toxin that binds to the extracellular domain of the membrane-anchored form of HB-EGF; it inhibits the soluble form of HB-EGF but does not bind to the other EGF family members. The anti-EGFR no. 225 Ab blocks the binding of EGF family members to the EGFR. AG1478 is an inhibitor of EGFR tyrosine kinase, which blocks the activation of EGFR. OSU8-1, CRM197, anti-EGFR no. 225, and AG1478 all block LL-37-induced phosphorylation of EGFR and keratinocyte migration (Figs. 2 and 3), which indicates that the LL-37-induced EGFR activation occurs via HB-EGF-mediated EGFR transactivation. Following EGFR activation, keratinocyte migration is induced via STAT3 phosphorylation. SOCS1/JAB and SOCS3/CIS3 negatively regulate this STAT3 pathway.

 
In a previous study, Tjabringa et al. (31) have shown that LL-37 activates airway epithelial cells, as demonstrated by its ability to activate ERK1/2 and to increase the release of IL-8. This activation requires the tyrosine kinase activity of the EGFR and involves the action of metalloproteinases and EGFR ligands, which indicates that the transactivation of EGFR is involved in this activation. The mechanism of this activation is quite similar to that of keratinocytes (Fig. 7). However, among the several EGFR ligands, no specific EGFR ligand for the transactivation of EGFR has been identified in airway epithelial cells. In keratinocytes, we found that HB-EGF is a mediator for LL-37-induced EGFR transactivation. The mechanism through which LL-37 activates metalloproteinase is still unclear. Several candidate molecules for the LL-37 receptor have been suggested, including the G protein-coupled formyl peptide receptor-like 1 (fPRL-1) (22, 24) and P2X7 (43). However, in airway epithelial cells, the activation was not inhibited by pertussis toxin or fPRL-1-antagonistic peptide, which indicates that fPRL-1 is not involved in transactivation of EGFR (31). Similarly, in keratinocytes, pertussis toxin did not inhibit LL-37-induced EGFR phosphorylation (data not shown), which suggests that fPRL-1 is not involved in LL-37-induced EGFR transactivation of keratinocytes. More recently, it has been suggested that LL-37 is able to cross the keratinocyte cell membrane and enter the cell (44). In this model, specific receptors are not required, and LL-37 may interact directly with the keratinocyte plasma membrane to cause conformational changes that activate indirectly a surface receptor that is linked to intracellular signaling molecules. If this is the case, it is possible that other highly cationic antimicrobial peptides, such as hBD1–3, also activate EGFR in keratinocytes. We tested this possibility and found that hBD1–3 phosphorylated EGFR in keratinocytes which suggests that the activation of keratinocytes is not unique to LL-37 among the antimicrobial peptides (our unpublished data).

The innate immune system is the first line of defense against microbial pathogens. Keratinocytes form a multilayered epidermis that separates the inner body from the outer environment and protects against a variety of microbial pathogens. Because the epidermis is the outermost layer of the body, epidermal keratinocytes are thought to be important components of innate immunity. Once the epidermis is disrupted by wounding, microbial pathogens can easily invade the body. Therefore, wound closure is an important issue for keratinocytes as participants in innate immunity. In this study, we have clearly demonstrated that LL-37 induces keratinocyte migration via EGFR transactivation. In the epidermis, bacterial contact, inflammation, and wounding are reported to stimulate keratinocytes to produce hCAP18/LL-37 (18, 36, 45). In addition to keratinocytes, granulocytes and skin mast cells produce hCAP18/LL-37 (4, 15). As hCAP18/LL-37 is up-regulated at the skin wound site (18), the present report strongly suggests that LL-37 induces keratinocyte migration to close the skin wound. In addition to its effects on keratinocytes, LL-37 can act on endothelial (24) and inflammatory cells, including neutrophils, monocytes, and T cells (22). Therefore, LL-37 may regulate skin wound healing through mechanisms that act directly on the cells within the wound environment rather than acting solely against microbial pathogens. Thus, hCAP18/LL-37 is a multifunctional mediator of innate immunity because it links host defenses and wound healing.

In the present study, the optimal concentration of LL-37 that induced keratinocyte migration was 1 µg/ml. The concentration of hCAP18/LL-37 at surgical wound sites has been reported to be ~2 µg/mg protein (19). Assuming that the protein concentration is similar to that in the serum (~70 mg/ml), the estimated concentration of hCAP18/LL-37 is 0.03 µg/ml. According to the data shown in Fig. 1, this concentration is insufficient to induce keratinocyte migration. However, immunohistochemical analysis has revealed that hCAP18/LL-37 is up-regulated, especially at the wound edge (19), which suggests that the local concentration of LL-37 at the wound edge, where keratinocytes are migrating, may be high enough to induce migration.

Although we have shown that LL-37 induces keratinocyte migration, it has been reported that human serum inhibits the antimicrobial activity of LL-37 (46), which raises the possibility that serum also inhibits LL-37-induced keratinocyte migration during wound healing in vivo. In an ex vivo wound healing model, re-epithelialization occurred in two steps without inflammation, i.e., simple migration and subsequent proliferation of keratinocytes to form a provisional neoepidermis (19). Our data indicate that endogenous LL-37 mediates this keratinocyte migration. This ex vivo wound healing model requires medium that contains at least 10% FBS for re-epithelialization (47, 48). Furthermore, this re-epithelialization is inhibited by anti-LL-37 Ab (19), which indicates that endogenous LL-37 is a mediator of re-epithelialization even in the presence of serum. In addition to the ex vivo wound healing model, LL-37-induced migration of leukocytes is independent of the presence of serum (22). Therefore, LL-37-induced keratinocyte migration may not be hindered by the presence of serum or wound fluid in vivo.

Growth factors, such as insulin-like growth factor-I and TGF-{alpha}, have been shown to induce the expression of hCAP18/LL-37 and hBD3 in human keratinocytes (49). In addition to these growth factors, EGF family members, including HB-EGF, are known to induce hCAP18/LL-37 in keratinocytes (our unpublished data). The EGF family is thought to be involved in the re-epithelialization of skin wounds (50). Among the EGF family, HB-EGF is a major growth factor component of wound fluid (51). Wound stimuli induce the shedding of HB-EGF from keratinocytes (37). In contrast, the mechanism of induction of hCAP18/LL-37 is poorly understood (4). The induction of hCAP18/LL-37 by EGF family members suggests that the high level of expression of hCAP18/LL-37 on the keratinocytes at the wound edge is due to HB-EGF. In psoriasis, hCAP18/LL-37 is up-regulated in the lesional epidermis (52). Because EGF family expression is enhanced in the lesional skin of psoriasis patients (53, 54), these elevated levels of hCAP18/LL-37 may be due to increased levels of EGF family proteins.

We also analyzed the regulation of STAT3 activation during LL-37-induced keratinocyte migration. The SOCS/CIS family negatively regulates the STAT pathways (34, 55, 56). However, the inhibitory functions of the SOCS/CIS family differ according to the cell type and cellular conditions. In this study, we showed that SOCS1/JAB or SOCS3/CIS3 block LL-37-induced keratinocyte migration, which suggests that migration is inhibited under conditions of high-level SOCS1/JAB or SOCS3/CIS3. Cytokines, such as IFN-{gamma}, IL-4, and IL-6, have been implicated in a variety of physiological and pathological conditions of the skin. IFN-{gamma} enhances SOCS1/JAB and SOCS3/CIS3 expression (41) in normal human keratinocytes. In addition, IL-4 and IL-6 enhance the expression of SOCS1/JAB and SOCS3/CIS3, respectively, in normal human keratinocytes (41). Therefore, the possibility exists that IFN-{gamma}, IL-4, and IL-6 affect wound healing in various inflammatory skin conditions by regulating keratinocyte migration via the induction of SOCS1/JAB or SOCS3/CIS3, which would lead to sustained wound healing in chronic ulcers. However, SOCS1/JAB and SOCS3/CIS3 were not induced by LL-37, which indicates that SOCS1/JAB and SOCS3/CIS3 do not act as self-limiting factors in LL-37-induced keratinocyte migration.

In conclusion, LL-37 induces keratinocyte migration via HB-EGF-mediated EGFR transactivation and STAT3 phosphorylation.


   Acknowledgments
 
We thank Teruko Tsuda and Eriko Tan for significant technical assistance.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from the Ministries of Health, Labor, and Welfare and Education, Culture, Sports, Science, and Technology of Japan. Back

2 S.T. and K.S. contributed equally to this article. Back

3 Address correspondence and reprint requests to Dr. Koji Sayama, Department of Dermatology, Ehime University School of Medicine, Toon-City, Ehime 791-0295, Japan. E-mail address: sayama{at}m.ehime-u.ac.jp Back

4 Abbreviations used in this paper: hBD, {beta}-defensin; EGF, epidermal growth factor; EGFR, EGF receptor; HB-EGF, heparin-binding EGF; BHE, bovine hypothalamic extract; Ax, adenovirus vector; JAB, Jak2 binding; moi, multiplicity of infection; SOCS, suppressor of a cytokine signaling; CIS, cytokine-inducible Src homology 2-containing protein; STAT3F, dominant-negative mutants of STAT3; fPRL-1, formyl peptide receptor-like 1. Back

Received for publication March 10, 2005. Accepted for publication July 22, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Ganz, T.. 2003. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:710.-720. [Medline]
  2. Lehrer, R. I., T. Ganz. 1999. Antimicrobial peptides in mammalian and insect host defence. Curr. Opin. Immunol. 11:23.-27. [Medline]
  3. Yang, D., O. Chertov, J. J. Oppenheim. 2001. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J. Leukocyte Biol. 69:691.-697. [Abstract/Free Full Text]
  4. Zaiou, M., R. L. Gallo. 2002. Cathelicidins, essential gene-encoded mammalian antibiotics. J. Mol. Med. 80:549.-561. [Medline]
  5. Ganz, T., M. E. Selsted, D. Szklarek, S. S. Harwig, K. Daher, D. F. Bainton, R. I. Lehrer. 1985. Defensins: natural peptide antibiotics of human neutrophils. J. Clin. Invest. 76:1427.-1435.
  6. Selsted, M. E., S. S. Harwig, T. Ganz, J. W. Schilling, R. I. Lehrer. 1985. Primary structures of three human neutrophil defensins. J. Clin. Invest. 76:1436.-1439.
  7. Jones, D. E., C. L. Bevins. 1993. Defensin-6 mRNA in human paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett. 315:187.-192. [Medline]
  8. Quayle, A. J., E. M. Porter, A. A. Nussbaum, Y. M. Wang, C. Brabec, K. P. Yip, S. C. Mok. 1998. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am. J. Pathol. 152:1247.-1258. [Abstract]
  9. Harder, J., J. Bartels, E. Christophers, J. M. Schroder. 2001. Isolation and characterization of human {beta}-defensin-3, a novel human inducible peptide antibiotic. J. Biol. Chem. 276:5707.-5713. [Abstract/Free Full Text]
  10. Harder, J., J. Bartels, E. Christophers, J.-M. Schroder. 1997. A peptide antibiotic from human skin. Nature 387:861.[Medline]
  11. Valore, E. V., C. H. Park, A. J. Quayle, K. R. Wiles, P. B. McCray, Jr, T. Ganz. 1998. Human {beta}-defensin-1: an antimicrobial peptide of urogenital tissues. J. Clin. Invest. 101:1633.-1642. [Medline]
  12. Harder, J., U. Meyer-Hoffert, K. Wehkamp, L. Schwichtenberg, J. M. Schroder. 2004. Differential gene induction of human {beta}-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J. Invest. Dermatol. 123:522.-529. [Medline]
  13. Sorensen, O. E., P. Follin, A. H. Johnsen, J. Calafat, G. S. Tjabringa, P. S. Hiemstra, N. Borregaard. 2001. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97:3951.-3959. [Abstract/Free Full Text]
  14. Murakami, M., T. Ohtake, R. A. Dorschner, B. Schittek, C. Garbe, R. L. Gallo. 2002. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J. Invest. Dermatol. 119:1090.-1095. [Medline]
  15. Di Nardo, A., A. Vitiello, R. L. Gallo. 2003. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170:2274.-2278. [Abstract/Free Full Text]
  16. Nizet, V., T. Ohtake, X. Lauth, J. Trowbridge, J. Rudisill, R. A. Dorschner, V. Pestonjamasp, J. Piraino, K. Huttner, R. L. Gallo. 2001. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414:454.-457. [Medline]
  17. Frohm, M., H. Gunne, A. C. Bergman, B. Agerberth, T. Bergman, A. Boman, S. Liden, H. Jornvall, H. G. Boman. 1996. Biochemical and antibacterial analysis of human wound and blister fluid. Eur. J. Biochem. 237:86.-92. [Medline]
  18. Dorschner, R. A., V. K. Pestonjamasp, S. Tamakuwala, T. Ohtake, J. Rudisill, V. Nizet, B. Agerberth, G. H. Gudmundsson, R. L. Gallo. 2001. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 117:91.-97. [Medline]
  19. Heilborn, J. D., M. F. Nilsson, G. Kratz, G. Weber, O. Sorensen, N. Borregaard, M. Stahle-Backdahl. 2003. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120:379.-389. [Medline]
  20. Elsbach, P.. 2003. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses?. J. Clin. Invest. 111:1643.-1645. [Medline]
  21. Yang, D., O. Chertov, S. N. Bykovskaia, Q. Chen, M. J. Buffo, J. Shogan, M. Anderson, J. M. Schroder, J. M. Wang, O. M. Howard, J. J. Oppenheim. 1999. {beta}-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525.-528. [Abstract/Free Full Text]
  22. De, Y., Q. Chen, A. P. Schmidt, G. M. Anderson, J. M. Wang, J. Wooters, J. J. Oppenheim, O. Chertov. 2000. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192:1069.-1074. [Abstract/Free Full Text]
  23. Davidson, D. J., A. J. Currie, G. S. Reid, D. M. Bowdish, K. L. MacDonald, R. C. Ma, R. E. Hancock, D. P. Speert. 2004. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172:1146.-1156. [Abstract/Free Full Text]
  24. Koczulla, R., G. von Degenfeld, C. Kupatt, F. Krotz, S. Zahler, T. Gloe, K. Issbrucker, P. Unterberger, M. Zaiou, C. Lebherz, et al 2003. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111:1665.-1672. [Medline]
  25. Sarret, Y., D. T. Woodley, K. Grigsby, K. Wynn, E. J. O’Keefe. 1992. Human keratinocyte locomotion: the effect of selected cytokines. J. Invest. Dermatol. 98:12.-16. [Medline]
  26. McCawley, L. J., P. O’Brien, L. G. Hudson. 1997. Overexpression of the epidermal growth factor receptor contributes to enhanced ligand-mediated motility in keratinocyte cell lines. Endocrinology 138:121.-127. [Abstract/Free Full Text]
  27. Daub, H., F. U. Weiss, C. Wallasch, A. Ullrich. 1996. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557.-560. [Medline]
  28. Miyamoto, S., H. Teramoto, J. S. Gutkind, K. M. Yamada. 1996. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 135:1633.-1642. [Abstract/Free Full Text]
  29. Prenzel, N., E. Zwick, H. Daub, M. Leserer, R. Abraham, C. Wallasch, A. Ullrich. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884.-888. [Medline]
  30. Asakura, M., M. Kitakaze, S. Takashima, Y. Liao, F. Ishikura, T. Yoshinaka, H. Ohmoto, K. Node, K. Yoshino, H. Ishiguro, et al 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8:35.-40. [Medline]
  31. Tjabringa, G. S., J. Aarbiou, D. K. Ninaber, J. W. Drijfhout, O. E. Sorensen, N. Borregaard, K. F. Rabe, P. S. Hiemstra. 2003. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171:6690.-6696. [Abstract/Free Full Text]
  32. Sano, S., S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi, H. Miura, K. Yoshikawa, S. Akira, J. Takeda. 1999. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18:4657.-4668. [Medline]
  33. Leonard, W. J., J. J. O’Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293.-322. [Medline]
  34. Duhe, R. J., L. H. Wang, W. L. Farrar. 2001. Negative regulation of Janus kinases. Cell Biochem. Biophys. 34:17.-59. [Medline]
  35. Tokumaru, S., K. Sayama, K. Yamasaki, Y. Shirakata, Y. Hanakawa, Y. Yahata, X. Dai, M. Tohyama, L. Yang, A. Yoshimura, K. Hashimoto. 2005. SOCS3/CIS3 negative regulation of STAT3 in HGF-induced keratinocyte migration. Biochem. Biophys. Res. Commun. 327:100.-105. [Medline]
  36. Midorikawa, K., K. Ouhara, H. Komatsuzawa, T. Kawai, S. Yamada, T. Fujiwara, K. Yamazaki, K. Sayama, M. A. Taubman, H. Kurihara, et al 2003. Staphylococcus aureus susceptibility to innate antimicrobial peptides, {beta}-defensins and CAP18, expressed by human keratinocytes. Infect. Immun. 71:3730.-3739. [Abstract/Free Full Text]
  37. Tokumaru, S., S. Higashiyama, T. Endo, T. Nakagawa, J. I. Miyagawa, K. Yamamori, Y. Hanakawa, H. Ohmoto, K. Yoshino, Y. Shirakata, et al 2000. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J. Cell Biol. 151:209.-220. [Abstract/Free Full Text]
  38. Sayama, K., Y. Shirakata, K. Midorikawa, Y. Hanakawa, K. Hashimoto. 1999. Possible involvement of p21 but not of p16 or p53 in keratinocyte senescence. J. Cell Physiol. 179:40.-44. [Medline]
  39. Shirakata, Y., H. Ueno, Y. Hanakawa, K. Kameda, K. Yamasaki, S. Tokumaru, Y. Yahata, M. Tohyama, K. Sayama, K. Hashimoto. 2004. TGF-{beta} is not involved in early phase growth inhibition of keratinocytes by 1{alpha},25(OH)2vitamin D3. J. Dermatol. Sci. 36:41.-50. [Medline]
  40. Boyden, S.. 1962. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J. Exp. Med. 115:453.-466. [Abstract]
  41. Yamasaki, K., Y. Hanakawa, S. Tokumaru, Y. Shirakata, K. Sayama, T. Hanada, A. Yoshimura, K. Hashimoto. 2003. Suppressor of cytokine signaling 1/JAB and suppressor of cytokine signaling 3/cytokine-inducible SH2 containing protein 3 negatively regulate the signal transducers and activators of transcription signaling pathway in normal human epidermal keratinocytes. J. Invest. Dermatol. 120:571.-580. [Medline]
  42. Miyake, S., M. Makimura, Y. Kanegae, S. Harada, Y. Sato, K. Takamori, C. Tokuda, I. Saito. 1996. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA 93:1320.-1324. [Abstract/Free Full Text]
  43. Elssner, A., M. Duncan, M. Gavrilin, M. D. Wewers. 2004. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1{beta} processing and release. J. Immunol. 172:4987.-4994. [Abstract/Free Full Text]
  44. Braff, M. H., M. A. Hawkins, A. Di Nardo, B. Lopez-Garcia, M. D. Howell, C. Wong, K. Lin, J. E. Streib, R. Dorschner, D. Y. Leung, R. L. Gallo. 2005. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174:4271.-4278. [Abstract/Free Full Text]
  45. Frohm, M., B. Agerberth, G. Ahangari, M. Stahle-Backdahl, S. Liden, H. Wigzell, G. H. Gudmundsson. 1997. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272:15258.-15263. [Abstract/Free Full Text]
  46. Johansson, J., G. H. Gudmundsson, M. E. Rottenberg, K. D. Berndt, B. Agerberth. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273:3718.-3724. [Abstract/Free Full Text]
  47. Inoue, M., G. Kratz, A. Haegerstrand, M. Stahle-Backdahl. 1995. Collagenase expression is rapidly induced in wound-edge keratinocytes after acute injury in human skin, persists during healing, and stops at re-epithelialization. J. Invest. Dermatol. 104:479.-483. [Medline]
  48. Kratz, G.. 1998. Modeling of wound healing processes in human skin using tissue culture. Microsc. Res. Tech. 42:345.-350. [Medline]
  49. Sorensen, O. E., J. B. Cowland, K. Theilgaard-Monch, L. Liu, T. Ganz, N. Borregaard. 2003. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol. 170:5583.-5589. [Abstract/Free Full Text]
  50. Martin, P.. 1997. Wound healing–aiming for perfect skin regeneration. Science 276:75.-81. [Abstract/Free Full Text]
  51. Marikovsky, M., K. Breuing, P. Y. Liu, E. Eriksson, S. Higashiyama, P. Farber, J. Abraham, M. Klagsbrun. 1993. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc. Natl. Acad. Sci. USA 90:3889.-3893. [Abstract/Free Full Text]
  52. Ong, P. Y., T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, T. Ganz, R. L. Gallo, D. Y. Leung. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347:1151.-1160. [Abstract/Free Full Text]
  53. Elder, J. T., G. J. Fisher, P. B. Lindquist, G. L. Bennett, M. R. Pittelkow, R. J. Coffey, Jr, L. Ellingsworth, R. Derynck, J. J. Voorhees. 1989. Overexpression of transforming growth factor {alpha} in psoriatic epidermis. Science 243:811.-814. [Abstract/Free Full Text]
  54. Cook, P. W., M. R. Pittelkow, W. W. Keeble, R. Graves-Deal, R. J. Coffey, Jr, G. D. Shipley. 1992. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res. 52:3224.-3227. [Abstract/Free Full Text]
  55. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, et al 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924.-929. [Medline]
  56. Alexander, W. S., R. Starr, J. E. Fenner, C. L. Scott, E. Handman, N. S. Sprigg, J. E. Corbin, A. L. Cornish, R. Darwiche, C. M. Owczarek, et al 1999. SOCS1 is a critical inhibitor of interferon {gamma} signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597.-608. [Medline]

Related articles in The JI:

IN THIS ISSUE

The JI 2005 175: 4159-4160. [Full Text]  



This article has been cited by other articles:


Home page
 J. Immunol.Home page
H.-M. Lee, J.-M. Yuk, D.-M. Shin, C.-S. Yang, K.-K. Kim, D.-K. Choi, Z.-L. Liang, J.-M. Kim, B. H. Jeon, C. D. Kim, et al.
Apurinic/Apyrimidinic Endonuclease 1 Is a Key Modulator of Keratinocyte Inflammatory Responses
J. Immunol., November 15, 2009; 183(10): 6839 - 6848.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. J. Oudhoff, K. L. Kroeze, K. Nazmi, P. A. M. van den Keijbus, W. van 't Hof, M. Fernandez-Borja, P. L. Hordijk, S. Gibbs, J. G. M. Bolscher, and E. C. I. Veerman
Structure-activity analysis of histatin, a potent wound healing peptide from human saliva: cyclization of histatin potentiates molar activity 1000-fold
FASEB J, November 1, 2009; 23(11): 3928 - 3935.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. B. Coffelt, S. L. Tomchuck, K. J. Zwezdaryk, E. S. Danka, and A. B. Scandurro
Leucine Leucine-37 Uses Formyl Peptide Receptor-Like 1 to Activate Signal Transduction Pathways, Stimulate Oncogenic Gene Expression, and Enhance the Invasiveness of Ovarian Cancer Cells
Mol. Cancer Res., June 1, 2009; 7(6): 907 - 915.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Tomasinsig, C. Pizzirani, B. Skerlavaj, P. Pellegatti, S. Gulinelli, A. Tossi, F. D. Virgilio, and M. Zanetti
The Human Cathelicidin LL-37 Modulates the Activities of the P2X7 Receptor in a Structure-dependent Manner
J. Biol. Chem., November 7, 2008; 283(45): 30471 - 30481.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Shimura, H. Kataoka, N. Ogasawara, E. Kubota, M. Sasaki, S. Tanida, and T. Joh
Suppression of proHB-EGF Carboxy-Terminal Fragment Nuclear Translocation: A New Molecular Target Therapy for Gastric Cancer
Clin. Cancer Res., June 15, 2008; 14(12): 3956 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
U. Dierssen, N. Beraza, H. H. Lutz, C. Liedtke, M. Ernst, H. E. Wasmuth, and C. Trautwein
Molecular Dissection of gp130-dependent Pathways in Hepatocytes during Liver Regeneration
J. Biol. Chem., April 11, 2008; 283(15): 9886 - 9895.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. Menard, V. Forster, M. Lotz, D. Gutle, C. U. Duerr, R. L. Gallo, B. Henriques-Normark, K. Putsep, M. Andersson, E. O. Glocker, et al.
Developmental switch of intestinal antimicrobial peptide expression
J. Exp. Med., January 21, 2008; 205(1): 183 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Yu, N. Mookherjee, K. Wee, D. M. E. Bowdish, J. Pistolic, Y. Li, L. Rehaume, and R. E. W. Hancock
Host Defense Peptide LL-37, in Synergy with Inflammatory Mediator IL-1beta, Augments Immune Responses by Multiple Pathways
J. Immunol., December 1, 2007; 179(11): 7684 - 7691.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K.-P. Xu, J. Yin, and F.-S. X. Yu
SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.
Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2832 - 2839.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
L. C. Huang, T. D. Petkova, R. Y. Reins, R. J. Proske, and A. M. McDermott
Multifunctional Roles of Human Cathelicidin (LL-37) at the Ocular Surface.
Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2369 - 2380.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Pochet, S. Tandel, S. Querriere, M. Tre-Hardy, M. Garcia-Marcos, M. De Lorenzi, M. Vandenbranden, A. Marino, M. Devleeschouwer, and J.-P. Dehaye
Modulation by LL-37 of the Responses of Salivary Glands to Purinergic Agonists
Mol. Pharmacol., June 1, 2006; 69(6): 2037 - 2046.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tokumaru, S.
Right arrow Articles by Hashimoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tokumaru, S.
Right arrow Articles by Hashimoto, K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS